Structure–Activity Relationship Study and Design Strategies of Hydantoin, Thiazolidinedione, and Rhodanine-Based Kinase Inhibitors: A Two-Decade Review

Muhammad Naufal; Elvira Hermawati; Yana Maolana Syah; Ace Tatang Hidayat; Ika Wiani Hidayat; Jamaludin Al-Anshori

doi:10.1021/acsomega.3c04749

journal article Open Access Jan 19, 2024

Structure–Activity Relationship Study and Design Strategies of Hydantoin, Thiazolidinedione, and Rhodanine-Based Kinase Inhibitors: A Two-Decade Review

Muhammad Naufal

Elvira Hermawati Yana Maolana Syah Ace Tatang Hidayat Ika Wiani Hidayat Jamaludin Al-Anshori

ACS Omega Vol. 9 No. 4 pp. 4186-4209 · American Chemical Society (ACS)

View at Publisher Save 10.1021/acsomega.3c04749

Topics

No keywords indexed for this article. Browse by subject →

References

101

[1]

10.1016/j.bioorg.2011.07.004

[2]

10.3892/ijmm.2017.3036

[3]

10.1186/s12943-018-0782-4

[4]

10.1016/s0065-230x(04)91001-9

[5]

Gerber D. E. American Family Physician (2008)

[6]

10.1200/jco.2005.01.016

[7]

Smith C.E.P. American Family Physician (2021)

[8]

Roskoski R.

[9]

FDA. FDA Grants Accelerated Approval to Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pirtobrutinib-relapsed-or-refractory-mantle-cell-lymphoma (accessed 2023).

[10]

Eli Lilly

[11]

10.1007/s40265-023-01860-1

[12]

Kinase drug discovery 20 years after imatinib: progress and future directions

Philip Cohen, Darren Cross, Pasi A. Jänne

Nature Reviews Drug Discovery 10.1038/s41573-021-00195-4

[13]

10.1345/aph.1r087

[14]

FDA New Drug Therapy Approvals 2019. https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2019 (accessed 2023).

[15]

FDA. FDA Approves First Therapy for Patients with Lung and Thyroid Cancers with a Certain Genetic Mutation or Fusion. https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-patients-lung-and-thyroid-cancers-certain-genetic-mutation-or-fusion (accessed 2023-12-12).

[16]

10.1021/acs.jmedchem.8b01040

[17]

10.1021/acsmedchemlett.3c00006

[18]

Buntz B.

[19]

10.1038/s41573-021-00252-y

[20]

10.1038/nchembio760

[21]

10.1021/acs.jmedchem.5b01073

[22]

10.1186/s13058-023-01679-4

[23]

10.1146/annurev-pharmtox-010715-103507

[24]

10.3390/cells9061427

[25]

10.1021/acs.biochem.2c00245

[26]

10.1021/acs.jmedchem.1c00217

[27]

10.1021/acsptsci.3c00078

[28]

Crystal Structure of the Catalytic Subunit of Cyclic Adenosine Monophosphate-Dependent Protein Kinase

Daniel R. Knighton, Jing Zheng, Lynn F. Ten Eyck et al.

Science 10.1126/science.1862342

[29]

10.1074/jbc.m207135200

[30]

10.1016/j.ccr.2005.01.007

[31]

Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors

Michele McTigue, Brion William Murray, Jeffrey H. Chen et al.

Proceedings of the National Academy of Sciences 10.1073/pnas.1207759109

[32]

10.1016/j.phrs.2022.106552

[33]

10.1016/j.phrs.2015.10.021

[34]

10.1016/j.bmcl.2011.01.071

[35]

10.1021/ml500394m

[36]

10.1124/jpet.112.197756

[37]

10.1097/fpc.0b013e32834aeedb

[38]

10.1124/mol.110.064683

[39]

Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

Chris Tran, Samedy Ouk, Nicola J. Clegg et al.

Science 10.1126/science.1168175

[40]

10.1016/j.fertnstert.2009.02.059

[41]

10.1172/jci15634

[42]

10.1021/acs.chemrev.7b00067

[43]

10.1021/acscombsci.7b00163

[44]

10.1016/j.ejmech.2018.12.066

[45]

10.1016/j.bmcl.2006.05.010

[46]

10.1158/1535-7163.mct-07-0477

[47]

Combination of 4-anilinoquinazoline and rhodanine as novel epidermal growth factor receptor tyrosine kinase inhibitors

Si-Ning Li, Yun-Yun Xu, Jia-Yu Gao et al.

Bioorganic & Medicinal Chemistry 10.1016/j.bmc.2015.04.065

[48]

10.1016/j.bioorg.2019.103035

[49]

10.1080/10406638.2020.1836004

[50]

10.1248/cpb.59.1124

Showing 50 of 101 references

Cited By

17

Isoniazid–rhodanine molecular hybrids: design, synthesis, antimycobacterial activity and computational validation

Gobind Kumar, Sahil Mishra · 2025

RSC Advances

Metrics

17

Citations

101

References

Details

Published: Jan 19, 2024
Vol/Issue: 9(4)
Pages: 4186-4209
License: View

Authors

M

Muhammad Naufal

Department of Chemistry, Padjadjaran University, Jalan Raya Bandung-Sumedang Km. 21, Jatinangor, Sumedang 45363, Indonesia

E

Elvira Hermawati

Department of Chemistry, Bandung Institute of Technology, Jalan Ganesha Nomor 10, Bandung, Jawa Barat 40132, Indonesia

Y

Yana Maolana Syah

Department of Chemistry, Bandung Institute of Technology, Jalan Ganesha Nomor 10, Bandung, Jawa Barat 40132, Indonesia

A

Ace Tatang Hidayat

Department of Chemistry, Padjadjaran University, Jalan Raya Bandung-Sumedang Km. 21, Jatinangor, Sumedang 45363, Indonesia

I

Ika Wiani Hidayat

Department of Chemistry, Padjadjaran University, Jalan Raya Bandung-Sumedang Km. 21, Jatinangor, Sumedang 45363, Indonesia

J

Jamaludin Al-Anshori

Department of Chemistry, Padjadjaran University, Jalan Raya Bandung-Sumedang Km. 21, Jatinangor, Sumedang 45363, Indonesia

Funding

Universitas Padjadjaran Award: 1549/UN6.3.1/PT.00/2023

Cite This Article

Muhammad Naufal, Elvira Hermawati, Yana Maolana Syah, et al. (2024). Structure–Activity Relationship Study and Design Strategies of Hydantoin, Thiazolidinedione, and Rhodanine-Based Kinase Inhibitors: A Two-Decade Review. ACS Omega, 9(4), 4186-4209. https://doi.org/10.1021/acsomega.3c04749

Structure–Activity Relationship Study and Design Strategies of Hydantoin, Thiazolidinedione, and Rhodanine-Based Kinase Inhibitors: A Two-Decade Review

You May Also Like